Market closedNon-fractional
Acumen Pharmaceuticals/ABOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Ticker
ABOS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Charlottesville, United States
Employees
52
Website
acumenpharm.com
ABOS Metrics
BasicAdvanced
$139M
Market cap
-
P/E ratio
-$1.05
EPS
0.15
Beta
-
Dividend rate
Price and volume
Market cap
$139M
Beta
0.15
Financial strength
Current ratio
30.197
Quick ratio
29.828
Long term debt to equity
11.625
Total debt to equity
11.671
Interest coverage (TTM)
-41.60%
Management effectiveness
Return on assets (TTM)
-16.82%
Return on equity (TTM)
-25.36%
Valuation
Price to book
0.53
Price to tangible book (TTM)
0.53
Price to free cash flow (TTM)
-2.425
Growth
Earnings per share change (TTM)
-5.24%
3-year earnings per share growth
-76.10%
What the Analysts think about ABOS
Analyst Ratings
Majority rating from 6 analysts.
ABOS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
-9.76%
Profit margin
0.00%
NaN%
ABOS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.28
-$0.24
-$0.28
-$0.25
-
Expected
-$0.35
-$0.27
-$0.26
-$0.26
-$0.29
Surprise
-19.08%
-9.77%
7.69%
-3.85%
-
ABOS News
AllArticlesVideos
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewsWire·2 months ago
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Acumen Pharmaceuticals stock?
Acumen Pharmaceuticals (ABOS) has a market cap of $139M as of July 06, 2024.
What is the P/E ratio for Acumen Pharmaceuticals stock?
The price to earnings (P/E) ratio for Acumen Pharmaceuticals (ABOS) stock is 0 as of July 06, 2024.
Does Acumen Pharmaceuticals stock pay dividends?
No, Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Acumen Pharmaceuticals dividend payment date?
Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Acumen Pharmaceuticals?
Acumen Pharmaceuticals (ABOS) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Acumen Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.